         |
List of publications since 1998
For
more detailed information select 'Abstract' or select 'Full Article' to
download a printable version. (PDF format).
| [Date] |
[Publication] |
 |
| 2007 |
Clin Exp Immunol 147:189-96 |
|
[403 Kb]
|
|
Pauls E, Senserrich J, Bofill M, Clotet B, Este JA.
Induction of interleukins IL-6 and IL-8 by siRNA.
|
| 2007 |
AIDS. 21(2):169-178 |
|
[168 Kb]
|
|
Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, Tambussi G, Llibre JM, Martinez-Picado J, Vidal F, Fumaz CR, Clotet B; The TIBET Study Group.
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
|
| 2007 |
AIDS Res Hum Retroviruses. 23:965-971. |
|
|
|
Sirera G, Videla S, López-Blázquez R, Llatjos M, Tarrats A, Castellà E, Grane N, Alcalde C, Tural C, Rey-Joly C, Clotet B.
Evolution of Cervical Cytologic Changes among HIV-Infected Women with Normal Cytology in the HAART Era.
|
| 2007 |
Top HIV Med. 15:119-25. |
|
|
|
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the Drug Resistance Mutations in HIV-1: 2007.
|
| 2007 |
HIV Clin Trials. 8:213-20. |
|
|
|
Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E.
Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
|
| 2007 |
J Virol. Jul 25; [Epub ahead of print] |
|
|
|
Gimenez-Barcons M, Clotet B, Martinez MA.
Endoribonuclease-prepared siRNAs induce effective and specific inhibition of HIV-1 replication.
|
| 2007 |
J Acquir Immune Defic Syndr. 45:479-81. |
|
|
|
Clotet B, Negredo E, Girard PM, Youle M, Neubacher D.
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
|
| 2007 |
Lancet. 370:39-48. |
|
|
|
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
|
| 2007 |
Hepatology. Aug 1; [Epub ahead of print] |
|
|
|
Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS.
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
|
| 2007 |
J Antimicrob Chemother. 60:436-439. |
|
|
|
Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
|
| 2007 |
J Infect Dis. 196:178-80 |
|
|
|
Clotet B.
CCR5 inhibitors: promising yet challenging.
|
| 2007 |
Clin Pharmacokinet. 46:85-92 |
|
|
|
Moltó J, Valle M, Blanco A, Negredo E, DelaVarga M, Miranda C, Miranda J, Domingo P, Vilaró J, Tural C, Costa J, Barbanoj MJ, Clotet B.
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
|
| 2007 |
AIDS Patient Care STDS. 2007 Aug;21(8):533-43 |
|
|
|
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, et al
TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals.
|
| 2007 |
AIDS. 21:2033-2042 |
|
|
|
Fox ZV, Geretti AM, Kjær J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD.
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
|
| 2007 |
J Viral Hepat. 14:704-13 |
|
|
|
Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B; and the CORAL-1 study group.
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
|
| 2007 |
AIDS. 21(10):1273-81. |
|
|
|
Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
|
| 2007 |
J Virol. 81:7559-70. |
|
|
|
Izquierdo-Useros N, Blanco J, Erkizia I, Fernández-Figueras MT, Borràs FE, Naranjo-Gómez M, Bofill M, Ruiz L, Clotet B, Martinez-Picado J.
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.
|
| 2007 |
Lancet.369:1169-78. |
|
|
|
Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
|
| 2007 |
AIDS. 21:721-32. |
|
|
|
Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group.
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
|
| 2007 |
AIDS. 21:657-63. |
|
|
|
Negredo E, Martínez E, Cinquegrana D, Estany C, Clotet B.
Therapeutic management of bone demineralization in the HIV-infected population.
|
| 2007 |
J Leukoc Biol. 82:72-8. |
|
|
|
de Arquer GR, Peña R, Cabrera C, Coma G, Ruiz-Hernandez R, Guerola R, Clotet B, Ruiz L, Esté JA, Calle ML, Bofill M.
Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patients.
|
| 2007 |
Hepatology. 45:899-910. |
|
|
|
Franco S, Parera M, Aparicio E, Clotet B, Martinez MA.
Genetic and catalytic efficiency structure of an HCV protease quasispecies.
|
| 2007 |
J Virol. 81:4713-21. |
|
|
|
Villena C, Prado JG, Puertas MC, Martínez MA, Clotet B, Ruiz L, Parkin NT, Menéndez-Arias L, Martinez-Picado J.
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
|
| 2007 |
Br J Clin Pharmacol. 63:715-21. |
|
|
|
Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B.
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
|
| 2007 |
J Virol. 81:2485-96. |
|
|
|
Fernàndez G, Clotet B, Martínez MA.
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.
|
| 2007 |
AIDS Care. 19:138-45. |
|
|
|
Fumaz CR, Muñoz-Moreno JA, Ballesteros AL, Paredes R, Ferrer MJ, Salas A, Fuster D, Masmitjà E, Pérez-Alvarez N, Gómez G, Tural C, Clotet B.
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
|
| 2007 |
Mol Biol Evol 24:382-7. |
|
|
|
Parera M, Fernàndez G, Clotet B, Martínez MA.
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.
|
| 2007 |
Virus Res. 123):161-9. |
|
|
|
Franco S, Tural C, Clotet B, Martínez MA.
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.
|
| 2008 |
AIDS. 22:367-76 |
|
|
|
Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD; EuroSIDA study group.
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
|
| 2008 |
Mol Pharmacol. [Epub ahead of print] |
|
|
|
Moncunill G, Armand-Ugon M, Clotet I, Pauls E, Ballana E, Llano A, Romagnoli B, Vrijbloed JW, Gombert FO, Clotet B, De Marco S, Este JA.
Anti-HIV Activity and Resistance Profile of the CXCR4 Antagonist POL3026.
|
| 2008 |
J Acquir Immune Defic Syndr. 47:36-49 |
|
|
|
Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT.
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
|
| 2008 |
AIDS. 22:203-10 |
|
|
|
Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U.
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
|
| 2008 |
AIDS. 22:23-31 |
|
|
|
Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté JA.
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
|
| 2008 |
J Antimicrob Chemother. 61:400-4 |
|
|
|
Negredo E, Puigdomènech I, Marfil S, Puig J, Pérez-Alvarez N, Ruiz L, Rey-Joly C, Clotet B, Blanco J.
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
|
| 2008 |
Virology. 372:421-9 |
|
|
|
Senserrich J, Pauls E, Armand-Ugón M, Clotet-Codina I, Moncunill G, Clotet B, Esté JA.
HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region.
|
| 2008 |
J Pharmacol Exp Ther. 324:558-67 |
|
|
|
Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, Martinez-Picado J.
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
|
| 2008 |
Virus Res. 131:260-70 |
|
|
|
Franco S, Clotet B, Martínez MA.
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
|
| 2008 |
J Antimicrob Chemother. 61:13-6 |
|
|
|
CLotet, B
Once-daily dosing of nevirapine in HAART.
|
| 2008 |
J Antimicrob Chemother. 61:206-9 |
|
|
|
Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
|
|
